CD274 and neoplasm: Champiat et al found that hyperprogression was associated with older age (≥65 years old) and worse OS in a cohort with 131 patients with various tumor types treated with monotherapy by anti‐PD‐1/PD‐L1 antibodies.30 Notably, they found that HPD was not related with tumor burden at baseline or tumor type.